Shots:
Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being
The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche…
Shots:
Fragmented workflows continue to be a major roadblock in the healthcare ecosystem, causing unnecessary delays in care delivery
Automated solutions help bridge the gaps resulting from disjointed workflows and expedite prior authorization, pharmacy routing, and patient onboarding
Colin Banas, CMO at DrFirst, joins PharmaShots in a discussion highlighting the company’s recent acquisition of Myndshft…
The peptide therapeutics market in North America and beyond is evolving fast, and 2025 is set to be a groundbreaking year.
Whether you’re a researcher involved in peptide drug clinical trials, an investor in different pharmaceutical companies, or just curious about the future of medicine and drug discovery, understanding various peptide therapeutics market trends will…
This exclusive breakfast meetup is designed for busy Clinical Trials Operation executives who want to gain high-value insights without committing to a full-day event.
For any queries, reach out to Tina Aston at ta@worldbigroup.com
Related Post: Drug Discovery and Innovation Programme 2025 | Sep 25-26 |Barcelona, Spain
A B2B event designed to connect Drug Discovery Experts, Biotech Innovation, and emerging technologies. This expert-led, two-day event blends keynotes, case studies, panel discussions, and 1:1 meetings to turn research into real-world impact.
For any queries, reach out to Tina Aston at ta@worldbigroup.com
Related Post: Clinical Trials Operations DACH 2025 | Sep 18 | Basel,…
Shots:
The EMA’s CHMP has granted positive opinions and approvals to 3 Biologics and 10 new chemical entities in July 2025, leading to treatments for patients and advances in the healthcare industry
The major highlighted drug was Roche’s Itovebi Secures the EC’s Approval for PIK3CA-mutated Breast Cancer
PharmaShots has compiled a list of 13 drugs…
Shots:
At this year’s European Association for the Study of the Liver (EASL) Congress in Amsterdam, Gilead shared new data and 29 abstracts, including three oral presentations. But the data wasn’t the only thing that got people talking about Gilead’s commitment to transforming the lives of people living with liver conditions
EASL saw the launch…
The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2025 takes place in Vösendorf, Austria on 24-25 November. The 5th anniversary edition of AUTOMA+ gathers leading innovators and IT professionals to discuss the directions of the advanced industry shift and celebrate this milestone together.
The 2-day agenda includes topics:
Ethical and human-centric AI;
Smart manufacturing techniques (digital…
BioPharma Deals: The Survival Series brings together leaders from biotech, pharma, investment, CRO/CDMO, legal, and advisory sectors for a high-impact event focused on pragmatic deal-making, new financing models, early IPOs, and unconventional partnerships.
This is not a conference about the distant future. It's a working summit for what can be done now. It's about survival,…
This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, Animal Health, and Biosimilars. Check out our full report below:
Novartis Reports Topline P-III (NEPTUNUS-1 & 2) Trials Finding on Ianalumab to Treat Active Sjögren’s Disease
Read More: Novartis
Stoke Therapeutics and Biogen Report First Patient Dosing in P-III (EMPEROR)…

